Blar i forfatter "Wallentin, Lars"

Viser treff 1-5 av 5

    • ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial 

      Ueland, Thor; Åkerblom, Axel; Ghukasyan, Tatevik; Michelsen, Annika; Becker, Richard C; Bertilson, Maria; Budaj, Andrzej; Cornel, Jan H; Himmelmann, Anders; James, Stefan K; Siegbahn, Agneta; Storey, Robert F; Kontny, Frederic; Aukrust, Pål; Wallentin, Lars (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-11-29)
      <p><i>Background and aims - </i>Activated leukocyte cell adhesion molecule (ALCAM) is upregulated during inflammation and involved in transmigration of leukocytes and T-cell activation. We hypothesized that ALCAM might be associated with recurrent events in patients with acute coronary syndromes (ACS). <p><i>Methods - </i>ALCAM was measured in serum obtained on admission, at discharge, 1 month and ...

    • C-X-C ligand 16 is an independent predictor of cardiovascular death and morbidity in acute coronary syndromes 

      Andersen, Thomas; Ueland, Thor; Ghukasyan Lakic, Tatevik; Åkerblom, Axel; Bertilsson, Maria; Aukrust, Pål; Michelsen, Annika E; James, Stefan K.; Becker, Richard C.; Storey, Robert F.; Wallentin, Lars; Siegbahn, Agneta; Kontny, Frederic (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-09-26)
      <i>Objective:</i> - The chemokine CXCL16 (C-X-C motif ligand 16) is a scavenger receptor for OxLDL (oxidized low-density lipoproteins) and involved in inflammation at sites of atherosclerosis. This study aimed to investigate the association of CXCL16 with clinical outcome in patients with acute coronary syndrome.<p> <p><i>Approach and Results:</i> - Serial measurements of CXCL16 were performed ...

    • Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial 

      Gregersen, Ida; Michelsen, Annika; Lunde, Ngoc Nguyen; Åkerblom, Axel; Lakic, Tatevik G.; Skjelland, Mona; Skagen, Karolina Ryeng; Becker, Richard C.; Lindbäck, Johan; Himmelmann, Anders; Solberg, Rigmor; Johansen, Harald Thidemann; James, Stefan K.; Siegbahn, Agneta; Storey, Robert F.; Kontny, Frederic; Aukrust, Pål; Ueland, Thor; Wallentin, Lars; Halvorsen, Bente (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-08-15)
      <i>Background</i> - The cysteine protease legumain is increased in patients with atherosclerosis, but its causal role in atherogenesis and cardiovascular disease is still unclear. The aim of the study was to investigate the association of legumain with clinical outcome in a large cohort of patients with acute coronary syndrome.<p><p> <i>Methods and Results</i> - Serum levels of legumain were ...

    • Osteoprotegerin is associated with major bleeding but not with cardiovascular outcomes in patients with acute coronary syndromes: Insights from the PLATO (Platelet Inhibition and Patient Outcomes) trial 

      Ueland, Thor; Åkerblom, Axel; Ghukasyan, Tatevik; Michelsen, Annika; Aukrust, Pål; Becker, Richard C.; Bertilsson, Maria; Himmelmann, Anders; James, Stefan K.; Siegbahn, Agneta; Storey, Robert F.; Kontny, Frederic; Wallentin, Lars (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-01-12)
      Background: <br>Elevated levels of osteoprotegerin, a secreted tumor necrosis factor–related molecule, might be associated with adverse outcomes in patients with coronary artery disease. We measured plasma osteoprotegerin concentrations on hospital admission, at discharge, and at 1 and 6 months after discharge in a predefined subset (n=5135) of patients with acute coronary syndromes in the PLATO ...

    • Pentraxin-3 vs C-reactive Protein and Other Prognostic Biomarkers in Acute Coronary Syndrome: A Substudy of the Platelet Inhibition and Patients Outcomes (PLATO) Trial 

      Kontny, Frederic; Andersen, Thomas; Ueland, Thor; Åkerblom, Axel; Lakic, Tatevik G.; Michelsen, Annika; Aukrust, Pål; Bertilsson, Maria; Becker, Richard C.; Himmelmann, Anders; James, Stefan K.; Siegbahn, Agneta; Storey, Robert F.; Wallentin, Lars (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-04-24)
      <i>Aims</i>: We investigated the dynamics, associations with patient characteristics, other biomarkers, and clinical outcomes of pentraxin 3 in acute coronary syndrome.<p><p> <i>Methods and results</i>: In multivariate analyses, pentraxin 3 measured in 5154 patients randomised in the Platelet Inhibition and Patients Outcomes (PLATO) trial (NCT00391872) was compared with leukocytes, high-sensitivity ...